Wall Street Thinks Archer Aviation Is a Buy. Here's Why I Don't.

Archer Aviation shares are down nearly 50% year to date despite an average analyst price target of $10.89, roughly $7 above the current share price. The company faces FAA certification delays for its Midnight eVTOL, a patent lawsuit with Vertical Aerospace, dilution concerns and competition from Joby and EHang. Q2 revenue was $5 million versus none a year earlier, while reported losses rose to $284.2 million; the article concludes the risks outweigh the long-term opportunity.

Analysis

The key valuation risk is duration: each certification or infrastructure delay pushes potential commercial cash flows further out while Archer continues funding development, making the equity more exposed to dilution and changing risk appetite than to near-term passenger demand. Commercial ties with United Airlines and Stellantis do not, by themselves, transfer certification risk or establish recurring aircraft economics. Their strategic value should be discounted until there is evidence of orders, deployment milestones, and economics.

Over the next 1–3 months, certification progress, cash use and financing terms matter more than analyst price targets; the lawsuit adds a binary legal overhang for both Archer and Vertical Aerospace, but the reported countersuit alone does not establish an operational injunction or damages. Over 6–18 months, the decisive test is whether Archer can convert flight testing into certification and a credible, capital-efficient operating network. Joby may benefit if relative execution becomes clearer, but China approval for EHang is not a proxy for U.S. certification or demand. A sharp rally based on partnerships or acquisition headlines could overstate their near-term financial contribution; equally, after a substantial drawdown, an outright short risks a squeeze on any milestone news. No valuation or cash-runway data are provided, so position sizing and standalone downside are difficult to underwrite.

Key Decisions for Investors

• Avoid treating the analyst target premium as a catalyst. Before adding or shorting ACHR, verify unrestricted cash, quarterly cash burn, expected financing needs and share-count dilution; absent those, keep exposure small or stay on watch.
• If seeking relative-value exposure, consider a modest, beta-aware ACHR-underweight/JOBY-overweight pair only if subsequent disclosures confirm a meaningful execution gap. Reassess on comparable certification milestones; the article alone is not enough to establish valuation or risk-adjusted superiority.
• Monitor FAA test and certification milestones, management guidance on launch timing, cash consumption, and any material court ruling. A sustained delay or worsening financing terms would strengthen the cautious thesis; credible certification progress without a deterioration in cash runway would weaken it.
• Do not infer near-term earnings sensitivity for UAL or STLA from their relationships with Archer. Look for binding commercial commitments and disclosed economics before trading either as a direct beneficiary.